天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (2): 220-224.doi: 10.11958/20211672

• 综述 • 上一篇    

PD-1抑制剂单抗治疗鼻咽癌的临床试验研究进展 #br#

雷小梅，瞿家权，谭潭
  

  1. 1南华大学衡阳医学院，附属郴州医院检验科（邮编421001）；2中山大学附属第八医院肿瘤科；3郴州市第一人民医院精准医学 中心
  • 收稿日期:2021-07-19 修回日期:2021-10-20 出版日期:2022-02-15 发布日期:2022-02-15
  • 通讯作者: 谭潭 E-mail:tantan1413@126.com
  • 基金资助:
    国家自然科学基金资助项目（81703043）；湖南省科技计划项目（2017SK51102、2017SK1103）；湖南省卫生厅项目（20200861）；陕西省精准医学中心重点实验室项目（KLTPM-SX2018-B5）

Progress in clinical trials of PD-1 inhibitor monoclonal antibody for nasopharyngeal carcinoma

LEI Xiaomei, QU Jiaquan, TAN Tan #br#   

  1. 1 Department of Laboratory, the Affiliated Chenzhou Hospital, Hengyang Medical School, University of South China,
    Chenzhou 421001, China; 2 Department of Oncology, the Eighth Affiliated Hospital, Sun Yat-sen University;
    3 Precision Medicine Center, Chenzhou First People's Hospital
  • Received:2021-07-19 Revised:2021-10-20 Published:2022-02-15 Online:2022-02-15

PDF (PC)

2457

摘要： 鼻咽癌是一种EB病毒（EBV）感染率高的头颈部恶性肿瘤，程序性死亡蛋白-1及其配体（PD-1/PD-L1）通 路的激活可能是EBV相关鼻咽癌免疫逃逸的机制之一。与化疗相比，免疫检查点抑制剂有不良反应小、生存获益更 长和耐受性更好等优势，但存在仅有少部分患者能受益的缺点。目前，至少有4种针对该通路的PD-1抑制剂单抗已 经在临床试验中取得了较好的效果，并且获批用于治疗复发或转移性鼻咽癌。就近年来已完成和正在进行的鼻咽 癌PD-1抑制剂的治疗策略、疗效评价和安全性的研究进行综述。

关键词: 鼻咽肿瘤, 免疫疗法, 程序性细胞死亡受体1, 免疫检查点抑制剂

Abstract: Nasopharyngeal carcinoma (NPC) is a head and neck malignant tumor with high infection rate of EBV. The activation of programmed death protein-1 and its ligand (PD-1/PD-L1) pathway may be one of the mechanisms of immune escape from EBV-associated NPC. Compared with chemotherapy, immune checkpoint inhibitors have less adverse reactions. Survival benefit is longer and the advantages of the tolerance is better, but there is only a small number of patients will benefit from faults. At present, at least four kinds of inhibitors targeting the pathway of PD-1 single resistance in clinical trials have achieved good results, and it has been approved for the treatment of recurrent or metastatic nasopharyngeal carcinoma. Recent completed and ongoing studies on the PD-1 inhibitor treatment strategy for NPC, the efficacy evaluation and safety studies were reviewed.

Key words: nasopharyngeal neoplasms, immunotherapy, programmed cell death 1 receptor, immune checkpoint inhibitor